Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years

2021 ◽  
Author(s):  
Alice Filippini ◽  
Massimo Gennarelli ◽  
Isabella Russo
Keyword(s):  
Gene Mutation ◽  
Cross Talk ◽  
Immune Cells ◽  
Autosomal Dominant ◽  
Missense Mutations ◽  
Leucine Rich Repeat ◽  
Common Cause ◽  
The Past ◽  
Multiple Processes ◽  
Lrrk2 Gene

Missense mutations in the leucine-rich repeat kinase-2 (LRRK2) gene represent the most common cause of autosomal dominant Parkinson's disease (PD). In the years LRRK2 has been associated with several organelles and related pathways in cell. However, despite the significant amount of research done in the past decade, the contribution of LRRK2 mutations to PD pathogenesis remains unknown. Growing evidence highlights that LRRK2 controls multiple processes in brain immune cells, microglia and astrocytes, and suggests that deregulated LRRK2 activity in these cells, due to gene mutation, might be directly associated with pathological mechanisms underlying PD. In this brief review, we recapitulate and update the last LRRK2 functions dissected in microglia and astrocytes. Moreover, we discuss how dysfunctions of LRRK2-related pathways may impact glia physiology and their cross-talk with neurons, thus leading to neurodegeneration and progression of PD.

scholarly journals Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?

2017 ◽  
Vol 45 (1) ◽  
pp. 261-267 ◽  
Author(s):  
Elisa Greggio ◽  
Luigi Bubacco ◽  
Isabella Russo
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cross Talk ◽  
Brain Function ◽  
Neuronal Development ◽  
Autosomal Dominant ◽  
Leucine Rich Repeat ◽  
Glia Cells ◽  
Multiple Processes ◽  
Brain Homeostasis

Evidence indicates that leucine-rich repeat kinase 2 (LRRK2) controls multiple processes in neurons and glia cells. Deregulated LRRK2 activity due to gene mutation represents the most common cause of autosomal dominant Parkinson's disease (PD). Protein kinase A (PKA)-mediated signaling is a key regulator of brain function. PKA-dependent pathways play an important role in brain homeostasis, neuronal development, synaptic plasticity, control of microglia activation and inflammation. On the other hand, a decline of PKA signaling was shown to contribute to the progression of several neurodegenerative diseases, including PD. In this review, we will discuss the accumulating evidence linking PKA and LRRK2 in neuron and microglia functions, and offer an overview of the enigmatic cross-talk between these two kinases with molecular and cellular implications.

scholarly journals An emerging role for LRRK2 in the immune system

2012 ◽  
Vol 40 (5) ◽  
pp. 1134-1139 ◽  
Author(s):  
Nicolas Dzamko ◽  
Glenda M. Halliday
Keyword(s):  
Risk Factor ◽  
Immune Cells ◽  
Potential Role ◽  
Autosomal Dominant ◽  
Association Studies ◽  
Genome Wide Association ◽  
Genome Wide Association Studies ◽  
Missense Mutations ◽  
Leucine Rich Repeat ◽  
Genome Wide

Missense mutations in LRRK2 (leucine-rich repeat kinase 2) contribute significantly to autosomal dominant PD (Parkinson's disease). Genome-wide association studies have suggested further that mutations in LRRK2 comprise a risk factor for sporadic PD. How LRRK2 contributes to PD, however, is largely unknown. Recent work has shown that LRRK2 is highly expressed in tissue and circulating immune cells and is suggestive of a potential role for LRRK2 in innate immunity. These studies and their potential implications for PD are discussed in the present paper.

scholarly journals Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson’s Disease Patients

2015 ◽  
pp. 117-121 ◽  
Author(s):  
Andres Felipe Duque ◽  
Juan Carlos Lopez ◽  
Helena Hernandez ◽  
Bruno Benitez ◽  
Juan Jose Yunis ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson Disease ◽  
Latin American ◽  
Autosomal Dominant ◽  
Late Onset ◽  
Causal Factor ◽  
Leucine Rich Repeat ◽  
Common Cause ◽  
Asymptomatic Control ◽  
Normal Controls

Introduction: Mutations in the leucine-rich repeat kinase 2 gene (LRRK2 or Dardarin) are considered to be a common cause of autosomal dominant and sporadic Parkinson´s disease, but the prevalence of these mutations varies among populations. Objective: to analysed the frequency of the LRRK2 p.G2019S mutation (c.6055G>A transition) in a sample of Colombian patients. Materials and Methods: In the present study we have analysed the frequency of the LRRK2 p.G2019S mutation in 154 patients with familial or sporadic Parkinson Disease, including early and late onset patients, and 162 normal controls. Results: Our results show occurrence of this mutation in two cases (2/154, 1.3%) with classical Parkinson´s signs, and one completely asymptomatic control (1/162, 0.6%). Conclusion: The p.G2019S mutation is not an important causal factor of Parkinson Disease in Colombia having similar frequencies to those reported in other Latin American populations.

scholarly journals Models for LRRK2-Linked Parkinsonism

2011 ◽  
Vol 2011 ◽  
pp. 1-16 ◽  
Author(s):  
Tianxia Li ◽  
DeJun Yang ◽  
Sarah Sushchky ◽  
Zhaohui Liu ◽  
Wanli W. Smith
Keyword(s):  
Dopaminergic Neurons ◽  
Autosomal Dominant ◽  
Dopaminergic System ◽  
Late Onset ◽  
Lewy Bodies ◽  
Leucine Rich Repeat ◽  
Protein Deposition ◽  
Lrrk2 Gene ◽  
The Brain ◽  
Potential Therapeutics

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by the selective loss of dopaminergic neurons and the presence of Lewy bodies. The pathogenesis of PD is not fully understood, but it appears to involve both genetic susceptibility and environmental factors. Treatment for PD that prevents neuronal death progression in the dopaminergic system and abnormal protein deposition in the brain is not yet available. Recently, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified to cause autosomal-dominant late-onset PD and contribute to sporadic PD. Here, we review the recent models for LRRK2-linked Parkinsonism and their utility in studying LRRK2 neurobiology, pathogenesis, and potential therapeutics.

scholarly journals P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity

2018 ◽  
Vol 475 (7) ◽  
pp. 1271-1293 ◽  
Author(s):  
Alexia F. Kalogeropulou ◽  
Jing Zhao ◽  
Marc F. Bolliger ◽  
Anna Memou ◽  
Shreya Narasimha ◽  
...  
Keyword(s):  
Kinase Activity ◽  
Rab Proteins ◽  
Missense Mutations ◽  
Leucine Rich Repeat ◽  
Lrrk2 Gene ◽  
Ubiquitin Binding Domain ◽  
Lrrk2 Kinase ◽  
Lrrk2 Kinase Activity ◽  
In Cells

Autosomal-dominant, missense mutations in the leucine-rich repeat protein kinase 2 (LRRK2) gene are the most common genetic predisposition to develop Parkinson's disease (PD). LRRK2 kinase activity is increased in several pathogenic mutations (N1437H, R1441C/G/H, Y1699C, G2019S), implicating hyperphosphorylation of a substrate in the pathogenesis of the disease. Identification of the downstream targets of LRRK2 is a crucial endeavor in the field to understand LRRK2 pathway dysfunction in the disease. We have identified the signaling adapter protein p62/SQSTM1 as a novel endogenous interacting partner and a substrate of LRRK2. Using mass spectrometry and phospho-specific antibodies, we found that LRRK2 phosphorylates p62 on Thr138 in vitro and in cells. We found that the pathogenic LRRK2 PD-associated mutations (N1437H, R1441C/G/H, Y1699C, G2019S) increase phosphorylation of p62 similar to previously reported substrate Rab proteins. Notably, we found that the pathogenic I2020T mutation and the risk factor mutation G2385R displayed decreased phosphorylation of p62. p62 phosphorylation by LRRK2 is blocked by treatment with selective LRRK2 inhibitors in cells. We also found that the amino-terminus of LRRK2 is crucial for optimal phosphorylation of Rab7L1 and p62 in cells. LRRK2 phosphorylation of Thr138 is dependent on a p62 functional ubiquitin-binding domain at its carboxy-terminus. Co-expression of p62 with LRRK2 G2019S increases the neurotoxicity of this mutation in a manner dependent on Thr138. p62 is an additional novel substrate of LRRK2 that regulates its toxic biology, reveals novel signaling nodes and can be used as a pharmacodynamic marker for LRRK2 kinase activity.

scholarly journals Novel Gene Deletion in NLRC4 Expanding the Familial Cold Inflammatory Syndrome Phenotype

2020 ◽  
Vol 11 ◽  
pp. 215265672092806
Author(s):  
Jack Jeskey ◽  
Akash Parida ◽  
Kelsey Graven ◽  
Robert Hostoffer
Keyword(s):  
Inflammatory Disease ◽  
Base Pair ◽  
Gene Deletion ◽  
Autosomal Dominant ◽  
Missense Mutations ◽  
Leucine Rich Repeat ◽  
Leucine Rich Repeat Domain ◽  
Symptomatic Case ◽  
Repeat Domain ◽  
Inflammatory Syndrome

Familial cold inflammatory syndrome (FCAS) is a rare, inherited inflammatory disease characterized by episodes of fever, rash, and arthralgias after exposure to cold stimuli. Previous literature has established FCAS linked to autosomal dominant mutations in the NLRP3 (CIAS1) and NLRP12 genes. Moreover, there has been recent evidence of NLRC4-inflammasomopathies. Although there have been cases of FCAS secondary to missense mutations in NLRC4, we report the first symptomatic case associated with a 93-base-pair in-frame deletion within Exon 5 of the leucine rich repeat domain.

A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease

The Lancet ◽  
2005 ◽  
Vol 365 (9457) ◽  
pp. 412-415 ◽  
Author(s):  
Alessio Di Fonzo ◽  
Christan F Rohé ◽  
Joaquim Ferreira ◽  
Hsin F Chien ◽  
Laura Vacca ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gene Mutation ◽  
Autosomal Dominant ◽  
Lrrk2 Gene

A frequent gene mutation associated with autosomal dominant Parkinson's disease

The Lancet ◽  
2005 ◽  
Vol 365 (9457) ◽  
pp. 412-415 ◽  
Author(s):  
A DIFONZO ◽  
C ROHE ◽  
J FERREIRA ◽  
H CHIEN ◽  
L VACCA ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gene Mutation ◽  
Autosomal Dominant

scholarly journals Sertoli-Leydig Cell Tumour and DICER1 Mutation: A Case Report and Review of the Literature

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
B. Wormald ◽  
S. Elorbany ◽  
H. Hanson ◽  
J. W. Williams ◽  
S. Heenan ◽  
...  
Keyword(s):  
Case Report ◽  
Gene Mutation ◽  
Leydig Cell ◽  
Autosomal Dominant ◽  
Review Of The Literature ◽  
Autosomal Dominant Fashion ◽  
Rare Tumours ◽  
Leydig Cell Tumour ◽  
Underlying Pathology ◽  
Leydig Cell Tumours

Sertoli-Leydig cell tumours of the ovary (SLCT) are rare tumours predominantly caused by mutations in the DICER1 gene. We present a patient with a unilateral SLCT who had an underlying germline DICER1 gene mutation. We discuss the underlying pathology, risks, and screening opportunities available to those with a mutation in this gene as SLCT is only one of a multitude of other tumours encompassing DICER1 syndrome. The condition is inherited in an autosomal dominant fashion. As such, genetic counselling is a key component of the management of women with SLCT.

scholarly journals Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Harry O. Orlans ◽  
Michelle E. McClements ◽  
Alun R. Barnard ◽  
Cristina Martinez-Fernandez de la Camara ◽  
Robert E. MacLaren
Keyword(s):  
Retinitis Pigmentosa ◽  
Autosomal Dominant ◽  
Gene Mutations ◽  
Adeno Associated Virus ◽  
Treatment Development ◽  
Common Cause ◽  
Toxic Protein ◽  
Rna Knockdown

AbstractRhodopsin (RHO) gene mutations are a common cause of autosomal dominant retinitis pigmentosa (ADRP). The need to suppress toxic protein expression together with mutational heterogeneity pose challenges for treatment development. Mirtrons are atypical RNA interference effectors that are spliced from transcripts as short introns. Here, we develop a novel mirtron-based knockdown/replacement gene therapy for the mutation-independent treatment of RHO-related ADRP, and demonstrate efficacy in a relevant mammalian model. Splicing and potency of rhodopsin-targeting candidate mirtrons are initially determined, and a mirtron-resistant codon-modified version of the rhodopsin coding sequence is validated in vitro. These elements are then combined within a single adeno-associated virus (AAV) and delivered subretinally in a RhoP23H knock-in mouse model of ADRP. This results in significant mouse-to-human rhodopsin RNA replacement and is associated with a slowing of retinal degeneration. This provides proof of principle that synthetic mirtrons delivered by AAV are capable of reducing disease severity in vivo.

Sign in / Sign up

Export Citation Format

Share Document